Dr. Wei He is Inventor, Founder & CEO of Zhejiang DTRM Biopharma Co. Ltd. (American-Chinese Joint Venture founded on November 11th, 2011 in China) and Zhejiang DTRM Biopharma LLC (Registered in Delaware, USA). DTRM Biopharma is a clinical-stage company conducting simultaneously clinical trials in USA and China, with patent-protected clinically differentiated target therapy and first-in-class oral doublet and triplet therapies along with $73 million raised in 6-years. Dr. He is the inventor and a co-inventor of 40 granted US patents and 3 issued patents in China, with pending patents in other Countries and Areas.

Prior to founding DTRM Biopharma, Dr. He spent 20 years with Morningside Venture, Adolor Corporation, Vitae Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, Aventis Pharmaceuticals, and Rhône-Poulenc Rorer Pharmaceuticals. Dr. He has a proven track record in the area of drug discovery, project management, and business development with increased responsibilities to leadership positions. Dr. He has discovered & developed many novel clinical drug candidates for treating cancers, cardiovascular diseases, gastroenterology disorders and diabetes including FDA-approved dual targeting medicine Viberzi (Eluxadoline or，JNJ27018966). Dr. He’s inventions and licensing have contributed to the L&A deals ranging from $300 million to $1.5 billion (Vitae-Boehringer Ingelheim, Adolor-Cubist, Furiex-Forest Lab/Allergan).

Dr. He was awarded with a B.S. degree in Chemistry from Peking University in 1985, and a member of the elite Chemistry Graduate Program sponsored by U.S. and China. Dr. He earned a Ph.D. degree in Chemistry followed by a post-doctoral research at The Ohio State University.

Dr. He is committed to develop better therapies for cancer patients in part due to his father died of cancer at age of 65